69034-13-5

Basic information

• Product Name: 4-METHOXYPHENOXYACETALDEHYDE DIETHYL ACETAL
• Synonyms: 4-METHOXYPHENOXYACETALDEHYDE DIETHYL ACETAL;p-methoxyphenoxyacetaldehyde diethyl acetal;Benzene,1-(2,2-diethoxyethoxy)-4-methoxy- (Related Reference);1-(2,2-diethoxyethoxy)-4-methoxybenzene;Benzene, 1-(2,2-diethoxyethoxy)-4-methoxy-
• CAS NO: 69034-13-5
• Molecular Formula: C₁₃H₂₀O₄
• Molecular Weight: 240.3
• Mol File: 69034-13-5.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 292-294 °C(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.03 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.000326mmHg at 25°C
• Refractive Index: n20/D 1.494(lit.)
• CAS DataBase Reference: 4-METHOXYPHENOXYACETALDEHYDE DIETHYL ACETAL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXYPHENOXYACETALDEHYDE DIETHYL ACETAL(69034-13-5)
• EPA Substance Registry System: 4-METHOXYPHENOXYACETALDEHYDE DIETHYL ACETAL(69034-13-5)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 69034-13-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H20O4/c1-4-15-13(16-5-2)10-17-12-8-6-11(14-3)7-9-12/h6-9,13H,4-5,10H2,1-3H3

Upstream product

• 150-76-5 4-methoxy-phenol 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 621-62-5 chloroacetaldehyde diethyl acetal 

Downstream Products

• 7182-32-3 2-phenyl-5-methoxybenzo[b]furan 
• 13391-27-0 5-methoxy-2-methylbenzofuran 

Relevant articles and documents

Enantio- and Diastereoselective, Complete Hydrogenation of Benzofurans by Cascade Catalysis

We report an enantio- and diastereoselective, complete hydrogenation of multiply substituted benzofurans in a one-pot cascade catalysis. The developed protocol facilitates the controlled installation of up to six new defined stereocenters and produces architecturally complex octahydrobenzofurans, prevalent in many bioactive molecules. A unique match of a chiral homogeneous ruthenium-N-heterocyclic carbene complex and an in situ activated rhodium catalyst from a complex precursor act in sequence to enable the presented process.

STABLE SOLID DISPERSIONS OF B-RAF KINASE DIMER INHIBITOR, METHODS OF PREPARATION, AND USES THEREFOR

Disclosed herein is a physically stable solid dispersion comprising Compound 1, i.e., the B-RAF kinase dimer inhibitor 1- ( (1S, 1aS, 6bS) -5- ( (7-oxo-5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl) oxy) -1a,6b-dihydro-1H-cyclopropa [b] benzofuran-1-yl) -3- (2, 4, 5-trifluorophenyl) urea and a specific stabilizing polymer, the method for preparing the same, and the uses of the solid dispersion. Also disclosed herein is the crystalline form of Compound 1.

Stable crystalline form A of B-RAF kinase dimer inhibitor

The invention relates to a stable crystalline form A of a B-RAF kinase dimer inhibitor 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-diazanaphthalene-4-yl) oxy)-1a, 6b-dihydro-1H-cyclopropyl[b] benzofuran-1-yl)-3-(2, 4, 5- trifluorophenyl) urea (hereinafter sometimes referred to as a compound 1), a preparation method of the crystalline Form A and therapeutic use of the crystalline Form A.